arginyl- 2,'6'- dimethyltyrosyl- lysyl- phenylalaninamide

01/01/2023 - "We describe the use of elamipretide in patients with mitochondrial disorders to provide dosing parameters in patients aged <12 years."
11/18/2022 - "Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice."
01/01/2022 - "Tetrapeptides with alternating cationic and aromatic residues such as SS-31 (elamipretide) show promise as therapeutic compounds for mitochondrial disorders. "
01/01/2022 - "However, supplement of elamipretide (SS-31) effectively reversed mitochondrial dysfunction. "
01/01/2022 - "Targeting mitochondrial dysfunction with elamipretide."

01/01/2020 - "A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy."
01/01/2020 - "Large clinical studies were presented such as RePOWER (observational study of patients with primary mitochondrial myopathy), MMPOWER (treatment with elamipretide in patients with primary mitochondrial myopathy), and ACT-ONE as well as new mouse models like the KPP mouse. "
11/20/2018 - "Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy."
04/03/2018 - "Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy."
01/01/2018 - "Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy."

06/01/2012 - "Postischemic administration of Bendavia protected against reperfusion injury in several distinct models of injury. "
01/01/2020 - "The aim of this study was to investigate whether bendavia has protective effects against ischemia/reperfusion damage using both in vivo and in vitro models. "
01/01/2023 - "Elamipretide mitigates ischemia-reperfusion injury in a swine model of hemorrhagic shock."
10/09/2022 - "Platelet Membrane-Encapsulated MSNs Loaded with SS31 Peptide Alleviate Myocardial Ischemia-Reperfusion Injury."
01/01/2020 - "However, the influence of bendavia on the blood-brain barrier (BBB) and neurons after brain ischemia/reperfusion damage is unclear. "

01/01/2022 - "A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects with Barth Syndrome (TAZPOWER). "
01/01/2022 - "A phase 3, observational, retrospective, and non-interventional study was designed to establish a natural history control (NHC) cohort of patients with Barth syndrome (BTHS) to provide further analysis of the efficacy of elamipretide observed in an open-label extension (OLE) phase of the TAZPOWER trial, a clinical trial that tested the efficacy of 40 mg daily of elamipretide in patients with BTHS. "
01/01/2022 - "Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome."
11/01/2023 - "Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data."
03/01/2023 - "Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide."

01/01/2014 - "However, when Bendavia perfusion began just 10 minutes after the onset of reperfusion, the protection against infarction and no-reflow was completely lost, indicating that the mechanism of protection is occurring early in reperfusion. "
01/01/2020 - "Compared to the vehicle group, bendavia administration (administered twice; immediately after reperfusion and 4 h later) attenuated the sensori-motor dysfunction and infarct formation independent of CBF variation. "
01/01/2014 - "Given that both infarction and no-reflow are related to increased cellular ROS, Bendavia's protective mechanism of action likely involves reduced ROS generation (as opposed to augmented scavenging) by endothelial and myocyte mitochondria. "
06/01/2012 - "Postischemic administration of Bendavia reduced infarct size in an in vivo sheep model by 15% (P=0.02) and in an ex vivo guinea pig model by 38% to 42% (P<0.05). "
04/21/2016 - "Administration of MTP-131 was not associated with a significant reduction in the primary endpoint, infarct size by creatine kinase-myocardial band (CK-MB) area under the curve (AUC) over 72 h (5785 ± 426 ng h/mL in placebo vs. 5570 ± 486 ng h/mL in MTP-131; ITALIC! P = NS). "